Please enable JavaScript to continue using this application.

Compare $PRLD vs $RCKT | Chartloom

Compare

$PRLD vs $RCKT

Prelude Therapeutics Inc · Rocket Pharmaceuticals Inc

PRLD

Prelude Therapeutics Inc

RCKT

Rocket Pharmaceuticals Inc

Compare $PRLD vs $RCKT

Comparing Prelude Therapeutics Inc and Rocket Pharmaceuticals Inc

PRLDPrelude Therapeutics Inc

RCKTRocket Pharmaceuticals Inc

PRLDPrelude Therapeutics Inc

Market cap

$310M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

5.94x

Rev growth (TTM)

—

YTD performance

42.5%

52W performance

173.9%

FCF yield

-10.7%

RCKTRocket Pharmaceuticals Inc

Market cap

$280M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

34.18x

Rev growth (TTM)

—

YTD performance

-26.0%

52W performance

-24.5%

FCF yield

-61.0%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

PRLD

RCKT

Detailed metrics comparison

PRLD

Prelude Therapeutics Inc

RCKT

Rocket Pharmaceuticals Inc

Market Cap

PRLD$310M

RCKT$280M

Enterprise Value

PRLD$284M

RCKT$76M

Price

PRLD$3.89

RCKT$2.56

P/E Ratio

PRLDN/A

RCKTN/A

P/S Ratio

PRLD13.82x

RCKT0.00x

EV/Sales

PRLD12.64x

RCKT0.00x

EV/EBITDA

PRLD0.00x

RCKT8.60x

P/B Ratio

PRLD2.19x

RCKT0.76x

P/FCF Ratio

PRLDN/A

RCKTN/A

EV/FCF

PRLD-8.53x

RCKT-0.45x

PEG Ratio

PRLDN/A

RCKTN/A

Forward P/E (NTM)

PRLDN/A

RCKTN/A

Forward P/S (NTM)

PRLD5.94x

RCKT34.18x

Revenue (TTM)

PRLD$22M

RCKT$0

Revenue Growth (YoY)

PRLDN/A

RCKTN/A

Forward Rev Growth

PRLD-14.3%

RCKT833.4%

Gross Margin (TTM)

PRLD0.0%

RCKT0.0%

Operating Margin (TTM)

PRLD0.0%

RCKT0.0%

EBITDA Margin (TTM)

PRLD-293.5%

RCKT0.0%

Net Margin (TTM)

PRLD-269.7%

RCKT0.0%

FCF Margin (TTM)

PRLD-148.3%

RCKTN/A

Net Income (TTM)

PRLD$-60M

RCKT$-17M

FCF (TTM)

PRLD$-33M

RCKT$-171M

EPS (TTM)

PRLD-$0.61

RCKT-$0.15

ROE (TTM)

PRLD-7535.0%

RCKT-576.0%

ROA (TTM)

PRLD-4439.0%

RCKT-490.0%

ROIC (TTM)

PRLD-7535.0%

RCKT-538.0%

Cash

PRLD$26M

RCKT$225M

Debt

PRLD$0

RCKT$21M

Net Cash/Debt

PRLD$26M

RCKT$203M

Current Ratio (TTM)

PRLD4.07x

RCKT9.24x

Quick Ratio (TTM)

PRLD3.99x

RCKT9.06x

Debt/Equity (TTM)

PRLD0.00x

RCKT0.06x

Debt/Assets (TTM)

PRLD0.0%

RCKT0.0%

Interest Coverage (TTM)

PRLDN/A

RCKTN/A

Net Debt/EBITDA (TTM)

PRLD0.00x

RCKT0.00x

Beta

PRLD1.19

RCKT0.48

52W Performance

PRLD173.9%

RCKT-24.5%

YTD Performance

PRLD42.5%

RCKT-26.0%

% from 52W High

PRLD-43.0%

RCKT-53.0%

% from 52W Low

PRLD238.3%

RCKT5.8%

Asset Turnover (TTM)

PRLD0.16x

RCKT0.00x

FCF Yield (TTM)

PRLD-10.7%

RCKT-61.0%

Earnings Yield (TTM)

PRLD-19.5%

RCKT-6.2%

Dividend Yield (TTM)

PRLDN/A

RCKTN/A

Rule of 40

PRLD-148.3

RCKT0.0

EV/GP/RG

PRLDN/A

RCKTN/A

Ticker research

View PRLD research View RCKT research

Metric	PRLD Prelude Therapeutics Inc	RCKT Rocket Pharmaceuticals Inc
Market & Valuation
Market Cap	$310M	$280M
Enterprise Value	$284M	$76M
Price	$3.89	$2.56
P/E Ratio	N/A	N/A
P/S Ratio	13.82x	0.00x
EV/Sales	12.64x	0.00x
EV/EBITDA	0.00x	8.60x
P/B Ratio	2.19x	0.76x
P/FCF Ratio	N/A	N/A
EV/FCF	-8.53x	-0.45x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	5.94x	34.18x
Revenue & Growth
Revenue (TTM)	$22M	$0
Revenue Growth (YoY)	N/A	N/A
Forward Rev Growth	-14.3%	833.4%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-293.5%	0.0%
Net Margin (TTM)	-269.7%	0.0%
FCF Margin (TTM)	-148.3%	N/A
Net Income (TTM)	$-60M	$-17M
FCF (TTM)	$-33M	$-171M
EPS (TTM)	-$0.61	-$0.15
ROE (TTM)	-7535.0%	-576.0%
ROA (TTM)	-4439.0%	-490.0%
ROIC (TTM)	-7535.0%	-538.0%
Financial Health
Cash	$26M	$225M
Debt	$0	$21M
Net Cash/Debt	$26M	$203M
Current Ratio (TTM)	4.07x	9.24x
Quick Ratio (TTM)	3.99x	9.06x
Debt/Equity (TTM)	0.00x	0.06x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.19	0.48
52W Performance	173.9%	-24.5%
YTD Performance	42.5%	-26.0%
% from 52W High	-43.0%	-53.0%
% from 52W Low	238.3%	5.8%
Efficiency & Yields
Asset Turnover (TTM)	0.16x	0.00x
FCF Yield (TTM)	-10.7%	-61.0%
Earnings Yield (TTM)	-19.5%	-6.2%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-148.3	0.0
EV/GP/RG	N/A	N/A
Ticker research	View PRLD research	View RCKT research

Valuation

P/S Ratio

RCKT

0.00x

PRLD

13.82x

EV/FCF

PRLD

-8.53x

RCKT

-0.45x

Growth & revenue

Forward Revenue Growth

RCKT

833.4%

PRLD

-14.3%

Profitability & performance

Gross Margin

PRLD

0.0%

RCKT

0.0%

ROE

RCKT

-576.0%

PRLD

-7535.0%

FCF Yield %

PRLD

-10.7%

RCKT

-61.0%

52-Week Performance

PRLD

173.9%

RCKT

-24.5%

Detailed metrics comparison

PRLD

Prelude Therapeutics Inc

RCKT

Rocket Pharmaceuticals Inc

Market Cap

PRLD$310M

RCKT$280M

Enterprise Value

PRLD$284M

RCKT$76M

Price

PRLD$3.89

RCKT$2.56

P/E Ratio

PRLDN/A

RCKTN/A

P/S Ratio

PRLD13.82x

RCKT0.00x

EV/Sales

PRLD12.64x

RCKT0.00x

EV/EBITDA

PRLD0.00x

RCKT8.60x

P/B Ratio

PRLD2.19x

RCKT0.76x

P/FCF Ratio

PRLDN/A

RCKTN/A

EV/FCF

PRLD-8.53x

RCKT-0.45x

PEG Ratio

PRLDN/A

RCKTN/A

Forward P/E (NTM)

PRLDN/A

RCKTN/A

Forward P/S (NTM)

PRLD5.94x

RCKT34.18x

Revenue (TTM)

PRLD$22M

RCKT$0

Revenue Growth (YoY)

PRLDN/A

RCKTN/A

Forward Rev Growth

PRLD-14.3%

RCKT833.4%

Gross Margin (TTM)

PRLD0.0%

RCKT0.0%

Operating Margin (TTM)

PRLD0.0%

RCKT0.0%

EBITDA Margin (TTM)

PRLD-293.5%

RCKT0.0%

Net Margin (TTM)

PRLD-269.7%

RCKT0.0%

FCF Margin (TTM)

PRLD-148.3%

RCKTN/A

Net Income (TTM)

PRLD$-60M

RCKT$-17M

FCF (TTM)

PRLD$-33M

RCKT$-171M

EPS (TTM)

PRLD-$0.61

RCKT-$0.15

ROE (TTM)

PRLD-7535.0%

RCKT-576.0%

ROA (TTM)

PRLD-4439.0%

RCKT-490.0%

ROIC (TTM)

PRLD-7535.0%

RCKT-538.0%

Cash

PRLD$26M

RCKT$225M

Debt

PRLD$0

RCKT$21M

Net Cash/Debt

PRLD$26M

RCKT$203M

Current Ratio (TTM)

PRLD4.07x

RCKT9.24x

Quick Ratio (TTM)

PRLD3.99x

RCKT9.06x

Debt/Equity (TTM)

PRLD0.00x

RCKT0.06x

Debt/Assets (TTM)

PRLD0.0%

RCKT0.0%

Interest Coverage (TTM)

PRLDN/A

RCKTN/A

Net Debt/EBITDA (TTM)

PRLD0.00x

RCKT0.00x

Beta

PRLD1.19

RCKT0.48

52W Performance

PRLD173.9%

RCKT-24.5%

YTD Performance

PRLD42.5%

RCKT-26.0%

% from 52W High

PRLD-43.0%

RCKT-53.0%

% from 52W Low

PRLD238.3%

RCKT5.8%

Asset Turnover (TTM)

PRLD0.16x

RCKT0.00x

FCF Yield (TTM)

PRLD-10.7%

RCKT-61.0%

Earnings Yield (TTM)

PRLD-19.5%

RCKT-6.2%

Dividend Yield (TTM)

PRLDN/A

RCKTN/A

Rule of 40

PRLD-148.3

RCKT0.0

EV/GP/RG

PRLDN/A

RCKTN/A

Ticker research

View PRLD research View RCKT research

Metric	PRLD Prelude Therapeutics Inc	RCKT Rocket Pharmaceuticals Inc
Market & Valuation
Market Cap	$310M	$280M
Enterprise Value	$284M	$76M
Price	$3.89	$2.56
P/E Ratio	N/A	N/A
P/S Ratio	13.82x	0.00x
EV/Sales	12.64x	0.00x
EV/EBITDA	0.00x	8.60x
P/B Ratio	2.19x	0.76x
P/FCF Ratio	N/A	N/A
EV/FCF	-8.53x	-0.45x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	5.94x	34.18x
Revenue & Growth
Revenue (TTM)	$22M	$0
Revenue Growth (YoY)	N/A	N/A
Forward Rev Growth	-14.3%	833.4%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-293.5%	0.0%
Net Margin (TTM)	-269.7%	0.0%
FCF Margin (TTM)	-148.3%	N/A
Net Income (TTM)	$-60M	$-17M
FCF (TTM)	$-33M	$-171M
EPS (TTM)	-$0.61	-$0.15
ROE (TTM)	-7535.0%	-576.0%
ROA (TTM)	-4439.0%	-490.0%
ROIC (TTM)	-7535.0%	-538.0%
Financial Health
Cash	$26M	$225M
Debt	$0	$21M
Net Cash/Debt	$26M	$203M
Current Ratio (TTM)	4.07x	9.24x
Quick Ratio (TTM)	3.99x	9.06x
Debt/Equity (TTM)	0.00x	0.06x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.19	0.48
52W Performance	173.9%	-24.5%
YTD Performance	42.5%	-26.0%
% from 52W High	-43.0%	-53.0%
% from 52W Low	238.3%	5.8%
Efficiency & Yields
Asset Turnover (TTM)	0.16x	0.00x
FCF Yield (TTM)	-10.7%	-61.0%
Earnings Yield (TTM)	-19.5%	-6.2%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-148.3	0.0
EV/GP/RG	N/A	N/A
Ticker research	View PRLD research	View RCKT research